Epigenetic restoration platform
exploratoryplatform · high · Wed Apr 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Enable rejuvenation of aged and injured cells to restore cellular function and potentially treat age-related diseases, including optic neuropathies.
Cellular rejuvenation platform based on epigenetic restoration and partial epigenetic reprogramming.
Described by the company as its core platform supporting therapeutic applications across diseases of aging and the listed ER-100 pipeline program.
ER-100 for optic nerve conditions
phase 1drug program · high · Mon Mar 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate ER-100 as a therapeutic program for optic neuropathies, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, with a focus on safety, tolerability, long-term health, and vision outcomes.
Single-dose clinical trial in adults with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy, including eye exams, laboratory tests, body-fluid sampling, quality-of-life questionnaires, and up to 5 years of follow-up.
Clinical trial published on ClinicalTrials.gov on 2026-03-02 to evaluate safety and tolerability of a single dose of ER-100 in people with glaucoma or NAION.
ER-100 optic neuropathy program
phase 1drug program · high · Mon Mar 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate ER-100 as a therapy for optic nerve conditions including open angle glaucoma and non-arteritic anterior ischemic optic neuropathy, with long-term monitoring of safety, health, and vision outcomes.
Single-dose clinical trial assessing safety and tolerability in adults with OAG or NAION, with eye exams, laboratory tests, body fluid sampling, quality-of-life questionnaires, and follow-up for up to 5 years.
ClinicalTrials.gov record for ER-100 safety study published on 2026-03-02.
Cellular reprogramming therapy for blindness
phase 1drug program · high · Tue Jan 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat blindness using cellular reprogramming technology in human volunteers.
Potent cellular reprogramming intervention intended to rejuvenate or restore function in eye disease; FDA-cleared first human test described as beginning shortly.
FDA approval to begin human testing, with first volunteer study expected to start shortly.
NAD+ amino acid salt anti-aging agents
preclinicalresearch program · medium · Thu Nov 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop amino acid salts of nicotinic acid mononucleotide and nicotinamide mononucleotide as anti-aging agents that increase cellular NAD+ levels.
Patent-described compositions using amino acid salts of nicotinic acid mononucleotide and nicotinamide mononucleotide.
Patent publication WO2019222368A1 published on 2019-11-21 with Life Biosciences Inc listed among assignees.
Patent excerpt states the salts increase cellular NAD+ levels.
